A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

Annals of Hematology

Volumn 89, Issue 10, 2010, Pages 1019-1027

  Chim, C S ^a   Lie, A K W ^a   Chan, E Y T ^a   Leung, Y Y ^a   Cheung, S C W ^a   Chan, S Y T ^a   Liang, Raymond ^a   Kwong, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CNS disease; Oligoclonal reconstitution; Staged approach; Survival; VAD; VTD

Indexed keywords

ANTICOAGULANT AGENT; BORTEZOMIB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; PARAPROTEIN; THALIDOMIDE; VINCRISTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN; PYRAZINE DERIVATIVE; VAD PROTOCOL;

ABDUCENS NERVE PARALYSIS; ADULT; AGED; ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW EXAMINATION; BONE MARROW TOXICITY; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM MYELOMA; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CYTOMEGALOVIRUS HEPATITIS; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIPLOPIA; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG FEVER; DRUG SENSITIVITY; ENTEROBACTERIACEAE INFECTION; EPIGASTRIC PAIN; EVENT FREE SURVIVAL; FATALITY; FEMALE; FOLLICULITIS; GASTROINTESTINAL TOXICITY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS SACRAL ULCER; HERPES ZOSTER; HICKMAN LINE INFECTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PLASMA CELL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSORY NEUROPATHY; SKIN NODULE; SPINAL CORD COMPRESSION; STEROID INDUCED DIABETES MELLITUS; THORACOLUMBAR SPINE; TREATMENT RESPONSE; TREMOR; VIRUS HEPATITIS; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77956707989     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0959-4     Document Type: Article

References (26)

1. M Attal JL Harousseau 2007 Role of autologous stem-cell transplantation in multiple myeloma Best Pract Res Clin Haematol 20 4 747 759 10.1016/j.beha.2007.09.006 1:CAS:528:DC%2BD2sXhsVSksbzI 18070717 (Pubitemid 350215383)
2. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis Blood 103 3175 3184 10.1182/blood-2003-06-2151 1:CAS:528:DC%2BD2cXjsVagsLk%3D 15070700 (Pubitemid 38451696)
3. PG Richardson B Barlogie J Berenson S Singhal S Jagannath D Irwin SV Rajkumar G Srkalovic M Alsina R Alexanian D Siegel RZ Orlowski D Kuter SA Limentani S Lee T Hideshima DL Esseltine M Kauffman J Adams DP Schenkein KC Anderson 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 2617 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D 12826635 (Pubitemid 36741588)
4. PG Richardson P Sonneveld MW Schuster D Irwin EA Stadtmauer T Facon JL Harousseau D Ben-Yehuda S Lonial H Goldschmidt D Reece JF San-Miguel J Blade M Boccadoro J Cavenagh WS Dalton AL Boral DL Esseltine JB Porter D Schenkein KC Anderson 2005 Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 2498 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D 15958804 (Pubitemid 41007864)
5. W Bensinger 2008 Stem-cell transplantation for multiple myeloma in the era of novel drugs J Clin Oncol 26 3 480 492 10.1200/JCO.2007.11.6863 1:CAS:528:DC%2BD1cXitVGnu78%3D 18056678 (Pubitemid 351171703)
6. J San-Miguel JL Harousseau D Joshua KC Anderson 2008 Individualizing treatment of patients with myeloma in the era of novel agents J Clin Oncol 26 16 2761 2766 10.1200/JCO.2007.15.2546 1:CAS:528:DC%2BD1cXnvVOhtr0%3D 18427148
7. N Mitsiades CS Mitsiades PG Richardson V Poulaki YT Tai D Chauhan G Fanourakis X Gu C Bailey M Joseph TA Libermann R Schlossman NC Munshi T Hideshima KC Anderson 2003 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 6 2377 2380 10.1182/blood-2002-06-1768 1:CAS:528:DC%2BD3sXit1egt70%3D 12424198 (Pubitemid 36302084)
8. CS Chim YY Hwang C Pang TW Shek 2009 Restoration of chemosensitivity by bortezomib: implications for refractory myeloma Nat Rev Clin Oncol 6 4 237 240 10.1038/nrclinonc.2009.15 1:CAS:528:DC%2BD1MXktVCmtLw%3D 19333230
9. JF San Miguel R Schlag NK Khuageva MA Dimopoulos O Shpilberg M Kropff I Spicka MT Petrucci A Palumbo OS Samoilova A Dmoszynska KM Abdulkadyrov R Schots B Jiang MV Mateos KC Anderson DL Esseltine K Liu A Cakana H van de Velde PG Richardson VISTA Trial Investigators 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 906 917 10.1056/NEJMoa0801479 1:CAS:528:DC%2BD1cXhtVGms77K 18753647
10. HE Oakervee R Popat N Curry P Smith C Morris M Drake S Agrawal J Stec D Schenkein DL Esseltine JD Cavenagh 2005 PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Br J Haematol 129 6 755 762 10.1111/j.1365-2141. 2005.05519.x 1:CAS:528:DC%2BD2MXms1ehs7c%3D 15953001 (Pubitemid 40904525)
11. R Popat HE Oakervee S Hallam N Curry L Odeh N Foot DL Esseltine M Drake C Morris JD Cavenagh 2008 Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up Br J Haematol 141 4 512 516 10.1111/j.1365-2141.2008.06997.x 1:CAS:528:DC%2BD1cXnt1eisLg%3D 18371113 (Pubitemid 351550543)
12. B Barlogie E Anaissie F van Rhee J Haessler K Hollmig M Pineda-Roman M Cottler-Fox A Mohiuddin Y Alsayed G Tricot V Bolejack M Zangari J Epstein N Petty D Steward B Jenkins J Gurley E Sullivan J Crowley JD Shaughnessy Jr 2007 Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Br J Haematol 138 2 176 185 10.1111/j.1365-2141.2007. 06639.x 1:CAS:528:DC%2BD2sXptFGgtLk%3D 17593024 (Pubitemid 46978271)
13. PR Greipp J San Miguel BG Durie JJ Crowley B Barlogie J Bladé M Boccadoro JA Child H Avet-Loiseau RA Kyle JJ Lahuerta H Ludwig G Morgan R Powles K Shimizu C Shustik P Sonneveld P Tosi I Turesson J Westin 2005 International staging system for multiple myeloma J Clin Oncol 20 15 3412 3420 10.1200/JCO.2005.04.242
14. BG Durie SE Salmon 1975 A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 3 842 854 10.1002/1097- 0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U 1:STN:280: DyaE28%2FktFCqtA%3D%3D 1182674
15. RA Kyle SV Rajkumar 2009 Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 1 3 9 10.1038/leu.2008.291 1:STN:280:DC%2BD1M%2FmslOgsA%3D%3D 18971951
16. AR Bradwell HD Carr-Smith GP Mead, et al. 2001 Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine Clin Chem 47 673 680 1:CAS:528:DC%2BD3MXis1Kju74%3D 11274017
17. J Bladé D Samson D Reece J Apperley B Björkstrand G Gahrton M Gertz S Giralt S Jagannath D Vesole 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol 102 5 1115 1123 10.1046/j.1365-2141.1998.00930.x 9753033 (Pubitemid 28435189)
18. CS Zent CS Wilson G Tricot S Jagannath D Siegel KR Desikan N Munshi D Bracy B Barlogie AW Butch 1998 Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation Blood 91 9 3518 3523 1:CAS:528:DyaK1cXislCnsbg%3D 9558413 (Pubitemid 28193907)
19. AB Fassas S Ward F Muwalla R Van Hemert K Schluterman S Harik G Tricot 2004 Myeloma of the central nervous system: strong association with unfavourable chromosomal abnormalities and other high-risk disease features Leuk Lymphoma 45 2 291 300 10.1080/10428190310001597964 15101714 (Pubitemid 38181431)
20. G Damaj M Mohty N Vey E Dincan R Bouabdallah C Faucher AM Stoppa JA Gastaut 2004 Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center Eur J Haematol 73 6 402 406 10.1111/j.1600-0609.2004.00331.x 1:STN:280:DC%2BD2crltVOisQ%3D%3D 15522061 (Pubitemid 39564362)
21. A Palumbo SV Rajkumar MA Dimopoulos PG Richardson J San Miguel B Barlogie J Harousseau JA Zonder M Cavo M Zangari M Attal A Belch S Knop D Joshua O Sezer H Ludwig D Vesole J Bladé R Kyle J Westin D Weber S Bringhen R Niesvizky A Waage M von Lilienfeld-Toal S Lonial GJ Morgan RZ Orlowski K Shimizu KC Anderson M Boccadoro BG Durie P Sonneveld MA Hussein International Myeloma Working Group 2008 Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2 414 423 10.1038/sj.leu.2405062 1:CAS:528:DC%2BD1cXhvVyltLc%3D 18094721 (Pubitemid 351255436)
22. Chan MH, Lau SM, Chen YT, Chan CC, Chan CH, Lam YK (2005) Thrombosis is uncommon in Chinese patients receiving thalidomide-experience in a regional hospital in Hong Kong. ASH Annual Meeting Abstracts 106, p 5149
23. BL Cheuk GC Cheung SW Cheng 2004 Epidemiology of venous thromboembolism in a Chinese population Br J Surg 91 4 424 428 10.1002/bjs.4454 1:STN:280:DC%2BD2c7lsVWgsA%3D%3D 15048741 (Pubitemid 38491110)
24. YK Chan KY Chiu SW Cheng P Ho 2004 The incidence of deep vein thrombosis in elderly Chinese suffering hip fracture is low without prophylaxis: a prospective study using serial duplex ultrasound J Orthop Surg (Hong Kong). 12 2 178 183 1:STN:280:DC%2BD2cnksFSrsw%3D%3D
25. WP Chan CK Lee YL Kwong CK Lam R Liang 1998 A novel mutation of Arg306 of factor V gene in Hong Kong Chinese Blood 91 4 1135 1139 1:CAS:528: DyaK1cXhtVGlu7g%3D 9454741
26. ZJ Jun T Ping Y Lei L Li SY Ming W Jing 2006 Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism Clin Lab Haematol 28 2 111 116 10.1111/j.1365-2257.2006.00757.x 1:STN:280:DC%2BD283itlajtg%3D%3D 16630215